Trevena

TRVN · OTC

$0.0005+$0.00 (+0.00%)TodayMarket closed · Oct 19, 10:53 AM ET

Prev close $0.0005

TRVN analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 30, 2024

Bull case

Trevena Inc demonstrates a promising outlook due to its innovative approach in developing CNS disorder treatments, particularly with compounds like TRV045, which offers a targeted mechanism that minimizes potential side effects compared to existing therapies. The company’s recent partnership with Premier, Inc broadens the reach of its product Olinvyk, potentially enhancing market access within a substantial healthcare network encompassing approximately 4,350 hospitals. The advancement in neuroprotective strategies, coupled with the growing approval of S1PR modulators in multiple sclerosis treatment, positions Trevena favorably amidst the evolving landscape of biopharmaceutical therapeutics.

Bear case

The financial data for Trevena Inc. indicates significant challenges, highlighted by a substantial year-over-year decline in research and development expenses of 56.2% to $1.9 million, which fell short of estimates, suggesting potential issues in the company’s development pipeline. General and administrative expenses also experienced a decline, but with operating losses widening to $10.1 million from $9.3 million in the previous year and a loss per share considerably greater than estimates, the company's financial health appears under pressure. Additionally, disappointing sales of Olinvyk at $84,000, likely impacted by product returns, further emphasize ongoing commercial struggles in a competitive market facing safety liability concerns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.